<DOC>
	<DOCNO>NCT00555022</DOCNO>
	<brief_summary>GSK1160724 potent mAChR antagonist , develop treatment chronic obstructive pulmonary disease ( COPD )</brief_summary>
	<brief_title>Effect GSK1160724 In Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Healthy male female subject . Female subject must nonchild bear potential . Aged 1855 year inclusive Nonsmokers Normal spirometry A sign date write informed consent obtain subject The subject capable give informed consent , include compliance requirement restriction list consent form Available complete study The subject great equal 50kg body mass index within range 19.0 29.9 kg/m2 inclusive Response ipratropium bromide Any clinically relevant important abnormality identify screen medical assessment ( physical examination/medical history ) , clinical laboratory test , ECG ( 12lead Holter ) A history breathing problem A mean QTc ( B ) value &gt; 450ms , QTc ( B ) 3 screen ECGs within 10 % mean , PR interval outside range 90210ms ECG suitable QT measurement screen A history elevate rest blood pressure mean blood pressure high 140/90 mmHg screen A mean heart rate outside range 4090 bpm inclusive screen History use tobacco nicotinecontaining product within 6 month screen , and/or positive urine cotinine test result screen Where participation study would result donation blood excess 500mL within 56 day period screen The subject currently take regular ( course ) medication , whether prescribe , include herbal remedy St John 's Wort etc . The subject take : prescription medication 14 day prior first dose study drug , Overthecounter ( OTC ) medications/preparations ( include herbal remedy , etc . ) exclude simple analgesic 48 hour prior first dose study drug , unless judge Investigator compromise subject 's safety influence outcome study . The subject participate study new molecular entity trial within period 3 month prior first dose study drug The subject test positive hepatitis C antibody ( third generation enzyme immunoassay ) , hepatitis B surface antigen HIV antibody ( test accord site SOP 's ) screening . The subject test positive drugsofabuse screen The subject test positive urine alcohol ( include ethanol ) screen The detection alcohol would exclusion screen would need negative predose study The subject unable use DISKUSâ„¢ and/or HandiHaler inhaler device correctly screen The subject suspect history alcohol abuse within six month previous screen visit The subject know allergy hypersensitivity magnesium stearate , milk protein excipient lactose monohydrate , iodine , ipratropium bromide , tiotropium bromide , atropine and/or derivatives The subject significant clinical history prostatic hypertrophy narrow angle glaucoma The subject receive allogeneic bone marrow transplant The subject claustrophobia may aggravate enter whole body plethysmography cabinet</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Muscarinic Receptor Antagonist ,</keyword>
	<keyword>Anticholinergic ,</keyword>
	<keyword>COPD ,</keyword>
	<keyword>FTIH ,</keyword>
	<keyword>Plethysmography</keyword>
</DOC>